

Michael F. Schaff to Present at the American Health Law Association's 2022 Health Care Transactions Program

04/25/22

Wilentz Shareholder Michael F. Schaff, Co-Chair of the Corporate, Health, and Cannabis law practice groups, will present "Overview of the Deal Process – A Roadmap Through the Paper Jungle" during the American Health Law Association's 2022 Health Care Transactions Program. The two-day program will provide insight into the business and legal issues involved in contemporary health care business transactions, including antitrust considerations, emerging care models, M&A trends, financing techniques, deal risk management strategies, and post-integration lessons.

The agenda for the presentation includes:

- Non-Disclosure/Confidentiality/Evaluation Material Agreements
- Letter of Intent/Term Sheet
- Choosing the Appropriate Acquisition Model
- Valuation and FMV
- Due Diligence
- Typical Contract Provisions
- Post-Closing Transaction Issues

[For more information and to register, please visit the event page.](#)

Attorney

- Michael F. Schaff

Practices

- Corporate
- Health Law
- Cannabis Law *

*Cannabis Law Disclaimer: Per federal law, under the Controlled Substances Act, marijuana is categorized as a Schedule I controlled substance. Possession, use, distribution, and/or sale of cannabis is a Federal crime and is subject to related Federal policy, regardless of any state law that may authorize certain marijuana activity. Compliance with state marijuana law does not equal compliance with federal law. Legal advice provided by Wilentz, Goldman & Spitzer, P.A. is designed to counsel clients regarding the validity, scope, meaning, and application of existing and/or proposed cannabis law. Wilentz, Goldman & Spitzer, P.A. will not provide guidance or assistance in circumventing or violating Federal or state cannabis law or policy, and any advice provided by Wilentz, Goldman & Spitzer, P.A. should not be construed as such.